Celera and Medco Join Forces to Study Statin Adherence Following KIF6 Testing

Researchers from Celera and Medco are investigating whether carriers of KIF6 who are made aware of their genetic risk factor and therapeutic advantage will stick to taking their statin drugs. But will it sway insurers?

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.